Fate Therapeutics, Inc. (FATE) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf, multiplexed-engineered cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). The company focuses on treating autoimmune diseases and cancer. This report covers the fiscal year ended December 31, 2025. As of December 31, 2025, the company employed 161 full-time employees.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $6,646 | $13,631 |
| Research & Development Expenses | $107,829 | $135,001 |
| General & Administrative Expenses | $46,521 | $74,169 |
| Net Loss | $(136,315) | $(186,262) |
| Cash, Cash Equivalents, and Investments | $205,100 | $270,669 |
| Accumulated Deficit | $(1,534,309) | $(1,397,994) |
Note: The filing text does not provide specific figures for operating margins or debt levels, as the company has no long-term debt and operates at a loss.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately 51% to $6.6 million, primarily due to the absence of a $5.0 million clinical development milestone recognized in 2024 under the Ono Pharmaceutical agreement.
- Expense Reduction: Total operating expenses decreased by approximately 31% to $154.4 million. This was driven by a $27.2 million decrease in R&D expenses and a $27.6 million decrease in G&A expenses, largely attributed to reduced stock-based compensation, lower legal/patent fees, and a corporate restructuring in August 2025 that reduced the workforce by approximately 12%.
- Impairment Reversal: Unlike 2024, which included a $14.7 million impairment charge on long-lived assets, no impairment was recorded in 2025.
- Interest Income: Total other income decreased to $11.4 million from $24.0 million, reflecting lower interest income on investments ($11.1 million in 2025 vs. $17.3 million in 2024).
Guidance, Outlook, and Risks
Outlook and Pipeline:
- FT819 (Autoimmunity): Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in April 2025 for Systemic Lupus Erythematosus (SLE). Phase 1 trials are ongoing in the U.S., U.K., and EU. Preliminary data showed significant reductions in disease activity scores (SLEDAI-2K) and B-cell depletion.
- FT825 (Solid Tumors): Phase 1 trial for HER2-targeted solid tumors is ongoing in collaboration with Ono Pharmaceutical.
- FT836 (Solid Tumors): Initiated Phase 1 clinical investigation in July 2025 for solid tumors without conditioning chemotherapy. First patient treated in November 2025.
- FT522 (Autoimmunity/Oncology): Completed Phase 1 in B-cell lymphoma; evaluating opportunities for autoimmune indications.
Liquidity: The company reported $205.1 million in cash, cash equivalents, and investments as of December 31, 2025. Management believes this is sufficient to fund operations for at least twelve months from the filing date. The company received $10.6 million in CIRM awards (FT819 and FT836) during 2025, recorded as liabilities.
Risks and Contingencies:
- Capital Requirements: The company anticipates continuing to incur significant losses and will require additional capital to advance clinical trials and commercialize products. Future financing may result in dilution.
- Regulatory Uncertainty: Novel iPSC-based therapies face uncertain regulatory pathways. The FDA has issued warnings regarding T-cell malignancies in CAR T-cell therapies.
- Legal Proceedings: The company is defending against a securities class action lawsuit (Hadian v. Fate Therapeutics) and related derivative actions alleging mismanagement regarding a terminated collaboration with Janssen. Motions to dismiss are pending.
- Intellectual Property: Reliance on licensed IP from academic institutions (e.g., MSKCC, Whitehead Institute) involves contingent milestone payments, including stock-price appreciation milestones.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $205.1 million cash balance against the projected burn rate, considering the company's history of significant net losses.
- Ono Collaboration Status: Confirm the timeline for future milestone payments and the progress of the joint development plan with Ono Pharmaceutical, which is the primary revenue source.
- FT819 Clinical Data: Review the full data set from the Phase 1 SLE trial to validate the preliminary efficacy and safety claims, particularly regarding the "conditioning-free" regimen.
- Legal Exposure: Monitor the status of the Hadian securities litigation and derivative suits, as a loss could result in significant financial liability or management distraction.
- Stock Price Milestones: Assess the fair value liability associated with the MSKCC stock price appreciation milestones, which fluctuate with the company's stock price.